MAP2K1(MEK1)
Sign in to save this workspaceUniProt Q02750 · PDB · AlphaFold · Substrate: ERK(K52R) · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Trametinib | 98.7% | 1.3% | 99.50 | 0.718 |
| 2 | Bosutinib | 89.8% | 10.2% | 87.22 | 0.555 |
| 3 | Pirtobrutinib | 81.8% | 18.2% | 99.49 | 0.656 |
| 4 | Cabozantinib | 81.2% | 18.8% | 92.73 | 0.751 |
| 5 | Binimetinib | 79.1% | 20.9% | 100.00 | 0.689 |
| 6 | Vemurafenib | 77.8% | 22.2% | 96.49 | 0.598 |
| 7 | Neratinib | 74.7% | 25.3% | 93.18 | 0.597 |
| 8 | Cobimetinib | 73.5% | 26.4% | 100.00 | 0.644 |
| 9 | Sunitinib | 68.7% | 31.3% | 91.73 | 0.524 |
| 10 | Tivozanib | 62.9% | 37.1% | 92.42 | 0.673 |
| 11 | Gilteritinib | 58.6% | 41.4% | 88.97 | 0.506 |
| 12 | Selumetinib | 54.4% | 45.6% | 100.00 | 0.640 |
| 13 | Zanubrutinib | 54.1% | 45.9% | 98.24 | 0.788 |
| 14 | Nintedanib | 46.3% | 53.7% | 90.23 | 0.608 |
| 15 | Capivasertib | 45.6% | 54.4% | 96.48 | 0.644 |
| 16 | Ibrutinib | 38.8% | 61.2% | 94.74 | 0.723 |
| 17 | Dasatinib | 34.5% | 65.5% | 87.97 | 0.699 |
| 18 | Abrocitinib | 31.8% | 68.2% | 99.50 | 0.581 |
| 19 | Baricitinib | 25.3% | 74.7% | 97.99 | 0.616 |
| 20 | Pacritinib | 19.3% | 80.7% | 88.64 | 0.452 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.63
- Epithelial log2(TPM+1): 5.25
- Fold change: 0.38
- Status: No significant change
Selectivity landscape vs inhibition on MAP2K1
Each point is one of the 92 approved drugs; color = inhibition % on MAP2K1.
Variants (1)
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…